| Literature DB >> 34319205 |
Nina D Wagner-Johnston1, Jeff Sharman2, Richard R Furman3, Gilles Salles4, Jennifer R Brown5, Tadeusz Robak6, Lin Gu7, Guan Xing7, Rebecca J Chan7, Nishanthan Rajakumaraswamy7, Ajay K Gopal8.
Abstract
Idelalisib is associated with increased occurrence of immune-related adverse events (irAEs). Clinical observations suggest a correlation between immune checkpoint inhibitor-induced irAEs and survival outcomes in patients with solid tumors; however, this relationship in hematologic malignancies is not well understood. In a post hoc analysis of 3 registrational trials, we explored the relationship between Grade ≥3 diarrhea/colitis and alanine/aspartate transaminase (ALT/AST) elevation incidences and efficacy endpoints in patients with indolent non-Hodgkin lymphoma (iNHL), follicular lymphoma (FL), and chronic lymphocytic leukemia treated with idelalisib. Grade ≥3 diarrhea/colitis was associated with higher overall response rate (ORR) and longer progression-free survival (PFS) for all subgroups. Grade ≥3 ALT/AST elevations were associated with improved duration of response and overall survival for all subgroups and improved ORR and PFS for patients with FL or iNHL. Our analysis in hematologic malignancies showed a trend correlating idelalisib-induced Grade ≥3 irAEs with improved efficacy.Entities:
Keywords: Idelalisib; PI3K inhibitor; chronic lymphocytic leukemia; follicular lymphoma; immune-related adverse event; indolent non-Hodgkin lymphoma
Mesh：
Substances：
Year: 2021 PMID： 34319205 PMCID： PMC9247649 DOI： 10.1080/10428194.2021.1948038
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022